Pharmacology and clinical experience with simvastatin

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 1, 2001, Pages 153-163

  Hess, D C ^a   Fagan, S C ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Atherosclerosis; LDL cholesterol; Myocardial infarction; Simvastatin; Stroke

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYCLOSPORIN; CYTOCHROME P450; ERYTHROMYCIN; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; NITRIC OXIDE SYNTHASE; PRAVASTATIN; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME REGULATION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MORBIDITY; MORTALITY; MYOPATHY; SMOOTH MUSCLE FIBER; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGED; ARTERIOSCLEROSIS; CHOLESTEROL, LDL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; SIMVASTATIN; TREATMENT OUTCOME;

EID: 0035002634     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.1.153     Document Type: Article

References (65)

1. Atherosclerosis-An inflammatory disease
2. The pathogenesis of atherosclerosis: Atherogenesis and inflammation
3. Distribution of cerebral atherosclerosis by geographic location, race and sex
4. Initiation of atherosclerotic lesions in cholesterol-fed rabbits, I. Focal increases in arterial LDL concentrations precede development of fatty streak lesions
5. Atherosclerosis: Basic mechanisms. Oxidation, inflammation and genetics
6. Compensatory enlargement of human atherosclerotic coronary arteries
7. Mechanisms of calcification in atherosclerosis
8. Coronary plaque disruption
9. Recently occluded intracranial and extracranial carotid arteries. Relevance of atherosclerotic plaque
10. Cholesterol reduction in cardiovascular disease
11. A receptor-mediated pathway for cholesterol homeostasis
12. Distribution of lipids in 8500 men with coronary artery disease
13. I. Reduction in incidence of coronary heart disease
14. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
15. ML-236A, ML-236B, ML-236C, new inhibitors of cholesterolgenesis produced by Penicillium citrinum
16. Natural statins and stroke risk
17. SIMVASTATIN: A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia
18. Comparison of properties of four inhibitors of 3-hydroxy-3 methylglutaryl-coenzyme A reductase
19. Clinical pharmacokinetics and practical applications of simvastatin
20. Vascular effects of statins in stroke
21. Anti-atherothrombotic properties of statins. Implications for cardiovascular event reduction
22. HMG-CoA reductase inhibitors. A promising approach to stroke prevention
23. Simvastatin, an HMG-CoA Reductase inhibitor, improves endothelial function within 1 month
24. Stroke prevention by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
25. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins
26. Vastatins inhibit cholesterol ester accumulation in human monocyte-derived macrophages
27. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
28. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia
29. Vastatins inhibit tissue factor expression in cultured human macrophages
30. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in Type IIa hypercholesterolemia
31. Direct vascular effects of HMG-CoA reductase inhibitors
32. HMG-CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits
33. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscles cells in culture
34. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts
35. Effect of statins on C-reactive protein in patients with coronary artery disease
36. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the scandinavian Simvastatin survival study
37. Statins and peripheral neuropathy
38. Stimulation of bone formation in vitro in rodents by statins
39. HMG-CoA reductase inhibitors and the risk of fractures
40. Do statins prevent both cardiovascular disease and fracture?
41. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study
42. Interactions with hydroxy methylglutaryl-coenzyme A reductase inhibitors
43. Simvastatin (MK-733): A potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolemia
44. Efficacy and tolerability of simvastatin (MK-733)
45. Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. A multicenter study. The Simvastatin Study Group
46. Efficacy and tolerability of medium-term treatment with simvastatin in primary hypercholesterolemia
47. Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolemia
48. Long-term safety and efficacy profile of simvastatin
49. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S)
50. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
51. Reduction of stroke incidence following myocardial infarction with pravastatin. The Cholesterol and Recurrent Events (CARE) Study
52. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range or initial cholesterol levels
53. Pravastatin therapy and the risk of stroke
54. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
55. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
56. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) Trial
57. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris
58. The design of a Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
59. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trail (ALLHAT)
60. Cost-effectiveness of cholesterol lowering. Results form the Scandinavian Simvastatin Survival Study (4S)
61. Cost effectiveness of 3-hydroxy-3-methyllutaryl-coenzyme A reductase inhibitors in the secondary prevention of cerebrovascular disease: Forecasting the incremennal benefits of preventing coronary and cerebrovascular events
62. Current and future treatment of hyperlipidemia: The role of statins
63. Reduction of LDL cholesterol by 25%-60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
64. Atorvastatin: An effective lipid-modifying agent in familial hypercholesterolemeia